Novavax says it could start making Omicron-specific vaccine in January By Reuters

by Msnbctv news staff

© Reuters. FILE PHOTO: Syringes with needles are seen in entrance of a displayed Novavax emblem on this illustration taken, November 27, 2021. REUTERS/Dado Ruvic/Illustration

(Reuters) – Novavax (NASDAQ:) Inc mentioned on Thursday it might start industrial manufacturing of a COVID-19 vaccine tailor-made for the Omicron coronavirus variant in January subsequent 12 months, whereas it assessments whether or not or not its present vaccine works towards the variant.

Laboratory (NYSE:) knowledge anticipated within the coming weeks will present whether or not antibodies from people who’ve beforehand acquired Novavax’s COVID-19 shot can neutralize the variant, in keeping with the corporate.

Novavax additionally mentioned it has began creating an Omicron-specific spike protein antigen and can start laboratory assessments of a brand new vaccine to focus on the variant in just a few weeks.

The Omicron coronavirus variant has shaken up markets and prompted world alarm over issues about whether or not it might evade safety offered by broadly used vaccines and delay the general public well being disaster.

Different vaccine makers together with Moderna (NASDAQ:) and Pfizer (NYSE:) have additionally begun engaged on Omicron-tailored COVID-19 pictures.

Novavax’s COVID-19 vaccine acquired its first emergency use approval in Indonesia in early November adopted by the Philippines.

Disclaimer: Fusion Media wish to remind you that the information contained on this web site shouldn’t be essentially real-time nor correct. All CFDs (shares, indexes, futures) and Foreign exchange costs will not be offered by exchanges however moderately by market makers, and so costs will not be correct and will differ from the precise market value, that means costs are indicative and never applicable for buying and selling functions. Subsequently Fusion Media doesn`t bear any accountability for any buying and selling losses you would possibly incur because of utilizing this knowledge.

Fusion Media or anybody concerned with Fusion Media is not going to settle for any legal responsibility for loss or harm because of reliance on the knowledge together with knowledge, quotes, charts and purchase/promote indicators contained inside this web site. Please be absolutely knowledgeable concerning the dangers and prices related to buying and selling the monetary markets, it is likely one of the riskiest funding kinds doable.

Source link

You may also like